KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Share-based Compensation (2016 - 2025)

Abbott Laboratories' Share-based Compensation history spans 17 years, with the latest figure at $113.0 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 1.8% year-over-year to $113.0 million; the TTM value through Dec 2025 reached $664.0 million, down 1.34%, while the annual FY2025 figure was $664.0 million, 1.34% down from the prior year.
  • Share-based Compensation for Q4 2025 was $113.0 million at Abbott Laboratories, down from $120.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $305.0 million in Q1 2022 and bottomed at $106.0 million in Q4 2021.
  • The 5-year median for Share-based Compensation is $127.5 million (2021), against an average of $165.3 million.
  • The largest annual shift saw Share-based Compensation increased 23.61% in 2021 before it fell 7.87% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $106.0 million in 2021, then grew by 8.49% to $115.0 million in 2022, then dropped by 0.87% to $114.0 million in 2023, then decreased by 2.63% to $111.0 million in 2024, then grew by 1.8% to $113.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Share-based Compensation are $113.0 million (Q4 2025), $120.0 million (Q3 2025), and $142.0 million (Q2 2025).